Management of Rabies in Humans
Author(s) -
Alan C. Jackson,
Mary Warrell,
Charles E. Rupprecht,
Hildegund C.J. Ertl,
Bernhard Dietzschold,
Michael OʼReilly,
Richard P. Leach,
Zhen F. Fu,
William H. Wunner,
Thomas P. Bleck,
Henry Wilde
Publication year - 2003
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/344905
Subject(s) - rabies , medicine , ribavirin , disease , rabies vaccine , immunology , virology , intensive care medicine , rabies virus , virus , hepatitis c virus
Rabies is a fatal disease in humans, and, to date, the only survivors of the disease have received rabies vaccine before the onset of illness. The approach to management of the rabies normally should be palliative. In unusual circumstances, a decision may be made to use an aggressive approach to therapy for patients who present at an early stage of clinical disease. No single therapeutic agent is likely to be effective, but a combination of specific therapies could be considered, including rabies vaccine, rabies immunoglobulin, monoclonal antibodies, ribavirin, interferon-alpha, and ketamine. Corticosteroids should not be used. As research advances, new agents may become available in the future for the treatment of human rabies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom